Relationship between <i>AHR</i> mRNA expression and classical clinical and pathological parameters in a series of 439 breast cancers.

<p>Relationship between <i>AHR</i> mRNA expression and classical clinical and pathological parameters in a series of 439 breast cancers.</p

mRNA expression levels of <i>AHR</i>, <i>AHRR</i> and <i>ARNT</i>, and of genes involved in inflammation, in MDA-MB-436 breast cancer cell line treated with two different <i>AHR</i> ligands.

<p>MDA-MB-436 cells were cultivated in absence (CTL) or in presence of TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) (10^-9M) or BaP (benzo[a]pyrene) (10^-6M) for 16 h. Cells were then lysed and mRNA extracted. mRNA expression levels of <i>AHR</i>, <i>AHRR</i> and <i>ARNT</i> (A), and of <i>IL1B</i>, <i>IL6</i>, <i>IL8</i> and <i>CXCR4</i> (B) were determined by qRT-PCR. All experiments were performed in triplicate. Results were expressed as mean +/- s.e.m and normalized so that the mean of the control cells was 1. Three levels of statistical significance are distinguished: *p-value<0.05; **p-value<0.01; ***p-value<0.001.</p

Relationship between <i>AHRR</i> mRNA expression and classical clinical and pathological parameters in a cohort of 439 breast cancers.

<p>Relationship between <i>AHRR</i> mRNA expression and classical clinical and pathological parameters in a cohort of 439 breast cancers.</p

Immunocytochemical staining for AhR and CD4 in breast tumors.

<p><b>a-b</b>, moderate AhR-expressing tumor cells. Note positive AhR staining in the intratumoral stroma. <b>c-d</b>, immunostaining for AhR (c) or CD4 (d) in the same tumor sample. Immunostaining for both AhR and CD4 is observed in stromal cells in the intratumoral compartment. T, tumor cells; S, intratumoral stroma. Original Magnification, x 20.</p

Clinical and pathological characteristics of patients in relation to metastasis-free survival (MFS).

<p>Clinical and pathological characteristics of patients in relation to metastasis-free survival (MFS).</p

Survival curves of two groups of patients according to <i>AHRR</i> mRNA expression level in the cohort of 439 breast tumors.

<p>AUC analysis was used to divide the population into two relevant <i>AHRR</i> expression subgroups.</p

Additional file 1: Figure S1. of CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer

A. EOC in situ surrounded by ascites. Cells Epcam− (red gate) were cell sorted and cultured. B. Phase contrast pictures of cells sorted in A. Scale bar: 50 μm C. Flow cytometry for every MSC markers on cells sorted in A. D. Cell sorted in fig. 1a were cultured for few days and stained with CD29 (green), CD105 (green), CD90 (red), CD73 (red) antibodies. Scale: 10 μm. Figure S2. OCCs were treated for 48 h with a blocking antibody against IL-6 (20 μg/mL). The percentage of live cells (green gate), apoptotic cells (red gate) and dead cells (black gate) are represented on the plot. Figure S3. A. Paraffin-embedded vimentin immunohistochemistry for the mouse group Control + MSC and Chemo + MSC. B. Confocal images for Epcam on 10μm sections of snap-frozen tumors. Scale: 100 μm. Figure S4. A. Relative quantification of IL-6 gene in RT-PCR on Ovcar3 (orange) and APOCC (purple) treated with SH IL-6 (SH) or scrambled (Scr), and MSC (grey) before (No cocu) or after co-incubation with OCCs scr or SH for 48 h. The histogram represents ratios between the transwell and the control condition of their 2–ΔΔCp real-time PCR values. B. Acquisition of the membrane in chemiluminescence. C. Hierarchical representation of the pixel density of each dot of the cytokine array. Figure S5. Phase contrast of OCCs after treatment with IL-8 (50 ng/ml), Dkk1 (20 ng/ml), IL-6 (50 ng/ml), MCP-1 (10 nM), CCL5 (100 ng/ml), CXCL12 (100 ng/ml), bFGF (10 ng/ml) for 48 h prior treatment with Carboplatin (200 μM) and Taxol (0.1 μM) for 24 h. Figure S6. A. Proteome profiler human phosphokinase array. B. Proteome profiler human phosphokinase array. C. Fold increase of pixel density of each condition compared to APOCC control (blue part) or to APOCC SH-IL6 (purple part). (PDF 1100 kb

Additional file 2: Table S1. of CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer

Primers list. (DOCX 14 kb